Biology of Juvenile Myoclonic Epilepsy
Launched by KING'S COLLEGE LONDON · Jan 12, 2018
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Biology of Juvenile Myoclonic Epilepsy (JME), is studying the genetic factors that cause JME, a type of epilepsy that usually starts in young people. Researchers are looking to gather blood samples and medical information from over 1,000 people diagnosed with JME across the UK, Europe, and North America. They will compare this data with information from 2,000 people without the condition. The aim is to identify the genetic causes of JME, which could lead to better treatments and help doctors recognize the condition earlier.
To be eligible for this study, participants must be diagnosed with Juvenile Myoclonic Epilepsy and be between the ages of 10 and 40. They should have experienced myoclonic seizures (which are quick muscle jerks) that started between ages 10 and 25, and their EEG tests (which measure brain activity) should show specific patterns typical of JME. Participants will be asked to provide blood samples and may undergo additional tests related to their condition. It’s important to note that the study is not accepting self-referrals, meaning individuals cannot sign themselves up; they need to be referred by a healthcare professional.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Juvenile Myoclonic Epilepsy in accordance with Consensus criteria
- • Age of myoclonus onset 10-25 years
- • Seizures comprising predominant or exclusive early morning myoclonus of upper extremities
- • EEG interictal generalized spikes and/or polyspike and waves with normal background
- • Current age 10-40 years
- Exclusion Criteria:
- • Myoclonus only associated with carbamazepine or lamotrigine therapy
- • EEG showing predominant focal interictal epileptiform discharges or abnormal background
- • Any evidence of progressive or symptomatic myoclonus epilepsy or focal seizures
- • Global learning disability
- • Dysmorphic syndrome
- • Unable to provide informed consent
- • Regrettably, we are currently unable to accept self-referrals to the BIOJUME study.
About King's College London
King's College London is a prominent research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the college leverages its extensive expertise in medicine, neuroscience, and public health to conduct rigorous studies aimed at improving patient outcomes. As a sponsor of clinical trials, King's College London prioritizes ethical standards, participant safety, and scientific integrity, fostering an environment that encourages groundbreaking research and the translation of findings into clinical practice. Through its state-of-the-art facilities and a diverse network of researchers, the institution strives to address critical health challenges and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Swansea, , United Kingdom
London, , United Kingdom
Liverpool, , United Kingdom
New York, New York, United States
New York, New York, United States
Columbus, Ohio, United States
Toronto, Ontario, Canada
Praha, , Czechia
Dianalund, , Denmark
Tallin, , Estonia
Paris, , France
Roma, , Italy
Drammen, , Norway
London, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
K Pal, MD PhD
Principal Investigator
King's College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials